Retractable Technologies Inc Dossier - Source-backed chat

Retractable Technologies Inc

RVPNYSE

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)1.13

Intrinsic Value $0.89median of 2 methodsbased on filings through 30 Jun 2026

Market Price $0.69Price as of 1 Oct 2026

UndervaluedIntrinsic value is 29% above the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $20.7M

Enterprise Value $19M

Shares Outstanding 29.9M diluted

Next Earnings Date13 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Retractable Technologies Inc. (RVP) is navigating a challenging transition period characterized by severe tariff pressures on its Chinese contract manufacturing (prevailing at 120% on needles and syringes) and high operating costs. While the company successfully grew its FY2025 revenues by 15.8% YoY to $38.3 million, it continues to generate substantial operating losses ($21.2 million in FY2025 and $6.2 million in Q1 2026). RVP is aggressively shifting production to its domestic facility in Little Elm, Texas, reaching 39% domestic production in Q1 2026 and executing a 16% workforce reduction in April 2026 to save $2.2 million annually. Although its balance sheet is supported by $34.4 million in debt and equity securities, the core business remains unprofitable at the operating level. A 'Hold' recommendation is advised until domestic manufacturing efficiencies are realized and operating margins stabilize.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

Domestic manufacturing transitions face equipment delays or higher-than-expected operational friction, keeping RVP reliant on Chinese imports subject to 120% tariffs. International sales growth stalls due to regulatory delays, and the cash burn accelerates, forcing the liquidation of its debt and equity securities portfolio at a loss.

Base CaseCentral scenario

The company continues to ramp up domestic manufacturing, successfully launching its 0.5 mL syringe production in H2 2026. The 16% workforce reduction yields the projected $2.2 million in annual savings, helping to narrow operating losses. However, high domestic manufacturing costs and residual tariff expenses on products that cannot yet be produced domestically keep the company in a net loss position through 2026.

Bull CaseUpside scenario

Retractable Technologies' bull case centers on its strategic shift toward domestic manufacturing to mitigate high tariff exposures on Chinese imports (which reached 130% on needles and syringes). By increasing U.S.-based production to approximately 39% of total output and executing a 16% workforce reduction in April 2026 to save $2.2 million annually, the company is actively optimizing its cost structure. Furthermore, the company's proprietary safety-engineered product portfolio (VanishPoint, Patient Safe, and EasyPoint) remains highly relevant under strict global healthcare safety regulations (OSHA, CDC, WHO) aimed at preventing needlestick injuries and bloodborne pathogen transmission.

Scenarios reflect our research view at the research date.

Key Investment Merits

Strong brand equity and clinical reputation of patented VanishPoint® and EasyPoint® safety medical products.
Substantial liquidity buffer with $34.4 million in debt and equity securities held at the end of FY2025.
Active mitigation of tariff risks, reducing Q1 2026 tariff expenses to under $12 thousand through strategic sourcing and domestic manufacturing expansion.

Key Investment Risks

Intense competition from medical supply giants (e.g., Becton Dickinson, Medtronic, Cardinal Health) with superior scale and distribution networks.
Severe tariff exposure, with a 120% prevailing rate on Chinese syringe and needle imports as of early 2026.
Persistent operating unprofitability, with an operating loss of $21.2 million in FY2025 and $6.2 million in Q1 2026.

Thesis Invalidation Triggers

Failure to achieve the projected $2.2 million in annual savings from the April 2026 workforce reduction.
Significant downward valuation adjustments or forced liquidations of the company's $34.4 million securities portfolio.
Delays in the domestic manufacturing ramp-up of the 0.5 mL syringe line planned for H2 2026.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.